Alexar Therapeutics Inc.
Creating an atopic dermatitis treatment from an LXR agonist
This article was originally published in Start Up
Alexar Therapeutics Inc. is developing a topical formulation of a Liver-X receptor agonist for atopic dermatitis, aka eczema. The company expects its formulation will safely treat the two key symptoms of this common skin disorder, by reducing inflammation on the skin surface and helping to repair the skin barrier.
You may also be interested in...
Unique market dynamics and plenty of exit options are attracting investors to dermatology. Profiles of Aclaris Therapeutics, Alexar Therapeutics, Rogne Bioscience, and Scioderm.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.